Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Multitrend Indo Tbk (BABY) vs Tempo Scan Pacific Tbk. (TSPC) Price & Performance

Multitrend Indo TbkTrade
Tempo Scan Pacific Tbk.Trade

Price performance (Past 24H)

Key statistics

Multitrend Indo Tbk vs Tempo Scan Pacific Tbk. — how do they compare? Multitrend Indo Tbk trades at Rp232 (market cap 776.51B, 45.12M 24h volume), while Tempo Scan Pacific Tbk. trades at Rp2,800 (market cap 12.54T, 323.8K 24h volume). The key difference: Tempo Scan Pacific Tbk. is far larger — about 16.1× Multitrend Indo Tbk's market cap, and Multitrend Indo Tbk is more actively traded (45.12M versus 323.8K). Which is the better fit depends on your goals.

BABYTSPC
Market Cap
776.51B12.54T
Volume
45.12M323.8K
Lot
451.21K3.24K
Turnover
11.77B902.58M
Average Price
260.942,787.45
Value
11.77B902.58M
Indicative Equilibrium Price
2322,800
Indicative Equilibrium Volume
546551

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

BABY
View details
TSPC
View details

About Multitrend Indo Tbk

PT Multitrend Indo Tbk ("Company") was established based on notary deed Drs. Wijanto Suwongso, SH, No. 20 dated September 7, 2004 and has beeen approved by the Ministry of Justice and Human Rights of Republic of Indonesia in its Decision Decree No. C-25996 HT.01.01.TH.2004 dated October 19 2004, and announced in the State Gazette No. 96 dated November 30, 2004, Supplement to the State Gazette of the Republic of Indonesia No. 11708. The Company started its commercial operations in 2004. PT Kanmo Retailindo are the parent entity and the ultimate parent of the Company.

Read more on BABY

About Tempo Scan Pacific Tbk.

PT. Tempo Scan Pacific Tbk (the Company) was established in the Republic of Indonesia dated 20 May 1970, under its original name PT Scanchemie within the framework of the Domestic Capital Investment Law No. 6 year 1968, as amended by Law No. 12 year 1970, based on Notarial Deed No. 37 of Ridwan Suselo, S.H. The company is famous for such pharmaceutical products as Bodrex, Hemaviton and Neo-Rheumacyl.

Read more on TSPC